3 stocks to turn $100 into $1,000 in 2024

06:40am, Thursday, 01'st Feb 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participa
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models
A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at t

Savara: A Speculative Play

11:50am, Sunday, 16'th Jul 2023
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate i

Why Shares of Savara Jumped on Tuesday

12:32pm, Tuesday, 16'th May 2023
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th

Why Shares of Savara Soared This Week

03:47pm, Friday, 27'th Jan 2023
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will

Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks

10:19am, Monday, 11'th Jul 2022 Zacks Investment Research
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.

3 Top Breakout Stocks to Add to Your Portfolio Now

11:10am, Friday, 08'th Jul 2022 Zacks Investment Research
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.

Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

01:40pm, Friday, 17'th Jun 2022 Zacks Investment Research
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE